About the Company
Compugen Ltd. (Hebrew: קומפיוג'ן) is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on COMPUGEN LTD
Need To Know: Analysts Just Made A Substantial Cut To Their Compugen Ltd. (NASDAQ:CGEN) Estimates
NasdaqCM:CGEN 1 Year Share Price vs Fair Value Explore Compugen's Fair Values from the Community and select yours ...
Compugen: Q2 Earnings Snapshot
Compugen Ltd. (CGEN) on Wednesday reported a loss of $7.3 million in its second quarter. On a per-share basis, the Holon, ...
Compugen Ltd.: Compugen Reports Second Quarter 2025 Results
First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in July 2025 Pooled analysis ...
Compugen to Release Second Quarter 2025 Results on ... - Morningstar
HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target ...
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
HOLON, ISRAEL, May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
CGEN | Compugen Ltd. Profile | MarketWatch
Company Profile Compugen Ltd. Azrieli Center 26 Harokmim Street Building D Holon, TA 58858 Phone972 3 765-8585 IndustryPharmaceuticals SectorHealth Care/Life Sciences Fiscal Year-end12/2025 ...
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6 ...
HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target ...
Shareholders in Compugen (NASDAQ:CGEN) are in the red if they invested ...
We wouldn't blame Compugen Ltd. (NASDAQ:CGEN) shareholders if they were still in shock after the stock dropped like a lead balloon, down 88% in just one year.
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical ...
HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today ...
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
Investors are always looking for stocks that are poised to beat at earnings season and Compugen Ltd. CGEN may be one such company. The firm has earnings coming up pretty soon, and events are ...
Compugen Discloses New Results Supporting CGEN-15052 as Novel Immune ...
Contacts Compugen Ltd. Tsipi Haitovsky Global Media Liaison +972-52-598-9892 tsipih@cgen.com ...
Similar Companies
Loading the latest forecasts...